High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort

Delphine Marotte,Jocelyn Gal,Renaud Schiappa,Mathieu Gautier,Rabia Boulahssass,Marie-Eve Chand-Fouche,Jean-Michel Hannoun-Levi

Clinical and Translational Radiation Oncology（2022）

引用 2|浏览7

暂无评分

摘要

•Intermediate/high risk elderly prostate cancer benefits less from received standards of care.•Age is an independent factor for disease control and tolerance.•Brachytherapy boost remains efficient and feasible in the elderly.•Careful discussion for super elderly patients (>80 y) is warranted.•Oncogeriatric assessment is necessary to identify best candidates.

查看译文

关键词

ADT,BT,bRFS,CSS,CT,CTCAE,CTV,D2cc,D90,D100,DFS,DNR,EBRT,EQD2,GI,GU,HDB,HR,IMRT,IR,ISUP,LDR,LR,lRFS,MFU,mRFS,MRI,NCCN,OAR,OS,PC,PET,PSA,pts,QoL,RCT,rRFS,TD,V100,V150,V200,Vr90,Vr100,Vu115,Vu125,3DRT

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要